All Stories

  1. Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood
  2. Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells
  3. TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer
  4. Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (Pueraria lobata)
  5. Abstract 11: Overexpression of midasin drives cancer stem cell dynamics in ESR1 mutant breast cancer
  6. Abstract 6768: Targeting the Her2 and ERα receptors has a significant impact on therapy-resistant ER-positive breast cancer
  7. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
  8. Correction: Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes
  9. Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  10. Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  11. Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  12. Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  13. Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  14. Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  15. Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  16. Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  17. Erratum: Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
  18. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
  19. Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma
  20. Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
  21. Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer
  22. Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive Disease
  23. Abstract PO2-24-04: Exploring the role and therapeutic potential of Ubiquitin Specific Peptidase 11 (USP11) in estrogen receptor positive breast cancer
  24. Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice
  25. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
  26. High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
  27. Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma
  28. Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
  29. Selective inhibition of CDK9 in triple negative breast cancer
  30. The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation
  31. Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition
  32. Deciphering Mutational Signature Dynamics in Hormone-Sensitive Breast Cancer During Treatment Adaptation.
  33. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
  34. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
  35. Distinguishing PIK3CA p.E545K Mutational Status from Pseudogene DNA with a Next-Generation ISFET Sensor Array
  36. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
  37. The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
  38. Abstract 1557: Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer
  39. Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  40. Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  41. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  42. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  43. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  44. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  45. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  46. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  47. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
  48. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer
  49. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence
  50. Harnessing the power of cryo-EM for development of cancer therapeutics: high-resolution structures of the human CDK-activating kinase bound to inhibitors
  51. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
  52. A comparison between Mini-loop mediated isothermal amplification and polymerase spiral reaction for selective amplification of short template DNA
  53. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
  54. Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer
  55. Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
  56. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
  57. HotspotESR1Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
  58. Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
  59. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease
  60. MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells
  61. Detection of Multiple Breast Cancer ESR1 Mutations on an ISFET Based Lab-on-Chip Platform
  62. BK polyomavirus (BKPyV) is a risk factor for bladder cancer through induction of APOBEC3-mediated genomic damage
  63. HotspotESR1mutations are multimodal and contextual drivers of breast cancer metastasis
  64. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942
  65. ESR1mutant breast cancers show elevated basal cytokeratins and immune activation
  66. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB
  67. Developing themes in targeted therapies for hormone receptor–positive breast cancer
  68. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer
  69. Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments
  70. The transcriptional repressor REV-ERB as a novel target for disease
  71. Preface
  72. 90 Years of progesterone: Ninety years of progesterone: the ‘other’ ovarian hormone
  73. Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer
  74. CDK7 inhibitors as anticancer drugs
  75. A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
  76. Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments
  77. Abstract P6-04-18: The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer
  78. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
  79. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
  80. Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
  81. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
  82. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
  83. Abstract 4834: CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers
  84. Abstract LB-224: Circulating tumor DNA for early detection and intervention in breast cancer: ctDNA profiles discriminate between healthy women in a true cancer screening setting and disease-free women on follow up
  85. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
  86. Author Correction: The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation
  87. Light-triggered enzymatic reactions in nested vesicle reactors
  88. Corrigendum: Inhibitor Selectivity for Cyclin‐Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study
  89. Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
  90. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation
  91. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells
  92. Erratum: Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
  93. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
  94. Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutations
  95. Inhibitor Selectivity for Cyclin‐Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study
  96. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
  97. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
  98. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
  99. Have you cleaned your stethoscope today?
  100. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
  101. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
  102. UK Breast Cancer Research Symposium 2016: Submitted Abstracts
  103. Abstract LB-339: Mutation analysis of cell-free DNA captures heterogeneity of individual circulating tumor cells in metastatic breast cancer
  104. Clinicopathologic significance of androgen receptor expression in invasive breast cancer: A comprehensive analysis in large cohorts
  105. Abstract P5-08-17: A study of c-Jun N-terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer
  106. Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes
  107. SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
  108. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
  109. Oestrogen receptors and epigenetics in breast cancer aetiology and outcome
  110. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer
  111. LRH-1 drives colon cancer cell growth by repressing the expression of theCDKN1Agene in a p53-dependent manner
  112. Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer
  113. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer
  114. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer
  115. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
  116. Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer
  117. The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin β 1
  118. Engineered repressors are potent inhibitors of androgen receptor activity
  119. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
  120. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells
  121. Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells
  122. Abstract 4762: Anti-Nicastrin antibodies for the treatment of endocrine resistant breast cancer .
  123. A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk
  124. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
  125. Abstract P2-10-22: Phosphorylation of Steroid Receptor Coactivator 3 (SRC3) at Ser543 is a novel independent prognostic marker in breast cancer
  126. Discovery of a New Class of Liver Receptor Homolog-1 (LRH-1) Antagonists: Virtual Screening, Synthesis and Biological Evaluation
  127. Development of a Novel Molecular Sensor for Imaging Estrogen Receptor-Coactivator Protein-Protein Interactions
  128. Abstract 4205: Identification of glycine N-methyltransferase-regulated genes in prostate cancer cells
  129. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
  130. Conversion of α-Amino Acids into Bioactive o-Aminoalkyl Resorcylates and Related Dihydroxyisoindolinones
  131. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer
  132. Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases
  133. A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration
  134. Concise, flexible syntheses of 4-(4-imidazolyl)pyrimidine cyclin-dependent kinase 2 (CDK2) inhibitors
  135. A simple laboratory practical to illustrate RNA mediated gene interference using drosophila cell culture
  136. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth
  137. The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells
  138. Abstract LB-178: Characterization of estrogen responses in breast cancer cell lines highlights ERα as an LRH-1 regulated gene
  139. The DEAD-box protein p72 regulates ERα-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer
  140. The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
  141. Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells
  142. Erratum: Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
  143. Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
  144. The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulators
  145. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity
  146. Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients
  147. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases
  148. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
  149. T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif
  150. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation
  151. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
  152. Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF
  153. Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF
  154. ICI182,780 Induces p21 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line
  155. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF
  156. Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines
  157. Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor
  158. The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity
  159. Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer
  160. Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function
  161. The Nuclear Oxysterol Receptor LXRα Is Expressed in the Normal Human Breast and in Breast Cancer
  162. T:G Mismatch-specific Thymine-DNA Glycosylase Potentiates Transcription of Estrogen-regulated Genes through Direct Interaction with Estrogen Receptor α
  163. Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study
  164. Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation
  165. Investigation of Estrogen Receptor Phosphorylation Using Phosphospecific Antibodies
  166. Purified malignant mammary epithelial cells maintain hormone responsiveness in culture
  167. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
  168. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
  169. Endocrine-responsive breast cancer and strategies for combating resistance
  170. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
  171. Analysis of estrogen‐responsive finger protein expression in benign and malignant human breast
  172. Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice
  173. Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
  174. Activation of Estrogen Receptor ? by S118 Phosphorylation Involves a Ligand-Dependent Interaction with TFIIH and Participation of CDK7
  175. Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization
  176. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata
  177. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers
  178. Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α
  179. Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance
  180. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo
  181. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo.
  182. Characterization of the Amino-terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and Yeast Cells
  183. Production and Characterization of Monoclonal Antibodies Recognising Defined Regions of the Human Oestrogen Receptor
  184. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region.
  185. Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor
  186. Retinoic acid receptor-beta: immunodetection and phosphorylation on tyrosine residues
  187. Immunodetection of multiple species of retinoic acid receptor α: Evidence for phosphorylation
  188. Developmental regulation of the sheep β‐lactoglobulin gene in the mammary gland of transgenic mice
  189. Characterisation of the alleles encoding ovine ß-lactoglobulins A and B
  190. Gene expression in the mammary gland
  191. The molecular manipulation of milk composition
  192. Characterization of the gene encoding ovine beta-lactoglobulin
  193. Complete nucleotide sequence of the genomic ovine β-lactoglobulin gene
  194. Estrogen Receptors and Anti-Estrogen Therapies
  195. Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer